摘要
RTS,S/AS01疟疾疫苗获得WHO批准大规模应用是人类抗击寄生虫感染史上的一个里程碑,然而RTS,S/AS01疫苗并非完美。本文从免疫学角度探讨了RTS,S/AS01疟疾疫苗存在的不足以及下一代疟疾疫苗研发可能面临的挑战。
RTS,S/AS01 vaccine has recently been recommended by the WHO for large-scale uses in malaria-endemic areas,which is a milestone in the history of the fight against parasitic infections.Nevertheless,RTS,S/AS01 vaccine is not perfect.Hereby,the shortages of RTS,S/AS01 malaria vaccine were discussed,and the potential challenges during the research and development of next-generation malaria vaccines were analyzed.
作者
冯高谦
FENG Gao-qian(Burnet Institute,Melbourne 3004,Australia;Department of Medicine,The University of Melbourne,Melbourne 3052,Australia)
出处
《中国血吸虫病防治杂志》
CAS
CSCD
北大核心
2021年第6期553-554,559,共3页
Chinese Journal of Schistosomiasis Control